GBM cell lines exposed to the methylating drug temozolomide upregulate ALKBH2 expression levels, and overexpression of ALKBH2 inversely increases cancer cell resistance to temozolomide and methanesulfonate. This evidence concerns the gene ALKBH2 and glioblastoma.